Company Overview - Gan Zhicao has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities International and Shenwan Hongyuan Hong Kong acting as joint sponsors [1] - The company is a digital-driven online comprehensive service provider in traditional Chinese medicine (TCM), covering online TCM diagnosis, TCM medical institution services, and TCM health products [1] - Gan Zhicao holds a leading position in the market, with a 4.9% market share among the top five online TCM service providers in China, and ranks first in the online TCM diagnosis service market with a 16.7% market share [1] Core Products and Services - The core products include the online diagnosis platform "Gan Cao Doctor," a SaaS and supply chain system "Gan Cao Cloud Manager" designed for TCM medical institutions, and the AI-assisted intelligent diagnosis program "Xuanqi Wendu," developed in collaboration with Zhejiang Chinese Medical University [1] - The company operates a smart shared pharmacy network consisting of 7 self-operated, 7 joint venture, and 52 outsourced pharmacies responsible for the preparation, processing, distribution, and delivery of traditional Chinese medicine [1] - Gan Zhicao has launched the "Gan Cao Life | Gan Zhi Yi" brand, which sells TCM health products [1] Industry Insights - The Chinese TCM industry is experiencing continuous growth, with the market size expected to reach 22,615 billion RMB by 2029 [2]

Company Overview - The company, Hangzhou Gan Zhi Cao Technology Co., Ltd., is a leading online TCM (Traditional Chinese Medicine) comprehensive service provider in China, focusing on online TCM diagnosis and treatment services, TCM medical institution services, and TCM health products [3][4]. - Established in 2015, the company is one of the earliest online TCM service providers in China, holding a market share of 4.9% in the online TCM comprehensive service market, ranking first among its peers [3][4]. Business Model - The company has developed an online diagnosis platform, Gan Cao Doctor, enabling TCM practitioners to provide medical services, and a SaaS and supply chain service system, Gan Cao Cloud Manager, designed for TCM medical institutions [4]. - It has established a smart shared pharmacy network consisting of seven self-operated regional pharmacies, seven joint venture pharmacies, and 52 outsourced pharmacies across China, facilitating the preparation, processing, dispensing, and delivery of TCM [4][5]. Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 is approximately RMB 603 million, RMB 690 million, and RMB 554 million, respectively [6]. - The profit and total comprehensive income for the same periods are RMB 1.875 million, RMB 10.156 million, and a loss of RMB 1.235 million [7]. - The gross profit margin for these periods is 22.8%, 23.4%, and 27% [8]. Industry Overview - The TCM industry in China is projected to grow from RMB 1,079.4 billion in 2019 to RMB 1,448.6 billion in 2024, with a compound annual growth rate (CAGR) of 6.1%, and is expected to reach RMB 2,261.5 billion by 2029, with a future five-year CAGR of 9.3% [11]. - The online TCM service market is anticipated to expand significantly, from RMB 2.7 billion in 2019 to RMB 13 billion in 2024, reflecting a CAGR of 36.5% [11][13].

Company Overview - The company, Hangzhou Gan Zhi Cao Technology Co., Ltd., is a leading online traditional Chinese medicine (TCM) service provider in China, focusing on online TCM diagnosis and treatment services, TCM medical institution services, and TCM health products [3][4] - Established in 2015, the company is one of the earliest online TCM service providers in China, holding a 4.9% market share, making it the largest player in the online TCM comprehensive service market [3][4] - The company has developed its own online diagnosis platform, Gan Cao Doctor, and a SaaS and supply chain service system, Gan Cao Cloud Manager, to enhance service delivery [4][5] Market Position - According to a report by Frost & Sullivan, the company ranks first in the online TCM diagnosis service market with a 16.7% market share as of 2024 [3] - The overall market for online TCM services is expected to grow significantly, with the online comprehensive TCM service market projected to expand from RMB 2.7 billion in 2019 to RMB 13 billion by 2024, reflecting a compound annual growth rate (CAGR) of 36.5% [10][12] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 is approximately RMB 603 million, RMB 690 million, and RMB 554 million, respectively [5][6] - The profit and total comprehensive income for the same periods are RMB 1.875 million, RMB 10.156 million, and a loss of RMB 1.235 million, respectively [6] - The gross profit margin for the same periods is 22.8%, 23.4%, and 27% [7] Industry Overview - The TCM industry in China is projected to grow from RMB 1,079.4 billion in 2019 to RMB 1,448.6 billion by 2024, with a CAGR of 6.1% [10] - The TCM diagnosis service segment is expected to reach approximately RMB 1,001.6 billion by 2024, growing at a CAGR of 10.1% [12] - The overall TCM market is transitioning from a drug-centric model to a more integrated healthcare and wellness development paradigm, supported by favorable policies and technological integration [12]